公开(公告)号：EP4454661A1

公开(公告)日：2024-10-30

申请号：EP22911237.0

申请日：2022-12-20

申请人： Toko Yakuhin Kogyo Co., Ltd. ,  Japan as Represented by Director-General of National Institute of Infectious Diseases

发明人： KAMISHITA, Taizou ,  MIYAZAKI, Takashi ,  SASAKI, Eita

IPC分类号： A61K39/39 ,  A61K39/145 ,  A61K39/215 ,  A61K47/02 ,  A61K47/04 ,  A61K47/18 ,  A61P31/14 ,  A61P31/16

摘要： The present disclosure provides a vaccine adjuvant agent comprising a polymer in which a constitutional unit is derived from acrylic acid, wherein the polymer has a carboxyl group content of 60.0 to 62.5 % by mass.

公开(公告)号：EP4108773A1

公开(公告)日：2022-12-28

申请号：EP21757741.0

申请日：2021-02-04

申请人： JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases

发明人： TAKAHASHI Yoshimasa ,  NITHICHANON Arnone ,  MATSUMURA Takayuki ,  SUZUKI Ryosuke ,  LIM, Chang Kweng ,  LERTMEMONGKOLCHAI, Ganjana

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P31/14 ,  C07K16/10

摘要： Provided is a flavivirus cross neutralizing antibody which has an excellent ability to control infection with suppressed ADE. This is a flavivirus cross neutralizing antibody that specifically binds to domains of E protein of flavivirus and thereby has an ability to control infection with at least two viruses included in the flavivirus. The domains of E protein include a plurality of domains including domain III. The flavivirus includes, for example, Zika virus, dengue virus types 1-4, and Japanese encephalitis virus.

公开(公告)号：EP3827842A1

公开(公告)日：2021-06-02

申请号：EP19842246.1

申请日：2019-07-22

申请人： JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases ,  Sumitomo Dainippon Pharma Co., Ltd.

发明人： TAKAHASHI, Yoshimasa ,  ADACHI, Yu ,  ATO, Manabu ,  FUKUSHIMA, Akihisa

IPC分类号： A61K39/145 ,  A61K39/39 ,  A61P31/16

摘要： The present invention provides a composition comprising a universal influenza vaccine antigen and a vaccine adjuvant.

公开(公告)号：EP3693006A1

公开(公告)日：2020-08-12

申请号：EP18864669.9

申请日：2018-10-04

申请人： Toko Yakuhin Kogyo Co., Ltd. ,  Tokyo Metropolitan Institute of Medical Science ,  Japan as Represented by Director-General of National Institute of Infectious Diseases ,  Kagoshima University ,  National University Corporation Ehime University

发明人： KAMISHITA, Taizou ,  MIYAZAKI, Takashi ,  KOHARA, Michinori ,  SANADA, Takahiro ,  HIASA, Yoichi ,  YOSHIDA, Osamu ,  KOHARA, Kyoko ,  HASEGAWA, Hideki

IPC分类号： A61K39/00 ,  A61K9/12 ,  A61K39/29 ,  A61K47/32 ,  A61P31/20 ,  A61P37/04

摘要： The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.

公开(公告)号：EP3566715A1

公开(公告)日：2019-11-13

申请号：EP19167809.3

申请日：2013-10-23

申请人： Japan as Represented by Director-General of National Institute of Infectious Diseases ,  Toko Yakuhin Kogyo Kabushiki Kaisha

发明人： Hasegawa, Hideki ,  Suzuki, Tadaki ,  Ainai, Akira ,  Kamishita, Taizou ,  Miyazaki, Takashi

IPC分类号： A61K39/145 ,  A61K9/06 ,  A61K9/72 ,  A61K47/32 ,  A61P31/16

摘要： The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant.

公开(公告)号：EP2770055A1

公开(公告)日：2014-08-27

申请号：EP14000648.7

申请日：2009-12-25

申请人： Toray Industries, Inc. ,  JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES ,  Tokyo Metropolitan Institute of Medical Science

发明人： Wakita, Takaji ,  Date, Tomoko ,  Takahashi, Hitoshi

IPC分类号： C12N15/09 ,  C07K16/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N7/00 ,  C07K14/005

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N7/00 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12N2770/24251

摘要： The present invention provides a nucleic acid comprises a 5' untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3' untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.

摘要翻译： 本发明提供的核酸包含5“非翻译区到NS3蛋白编码区，NS4A到蛋白编码区，NS4B在蛋白编码区，NS5A上蛋白编码区，NS5B到蛋白编码区，以及3”非翻译区 丙型肝炎病毒基因组中，worin所述核酸具有核苷酸取代导致脱离组包括M中选择的一个或多个氨基酸取代的（1205）K，F（1548）L，C（1615）W，T（1652）N ，A（2196）T，A（2218）S，H（2223）Q，Q（2281）R，K（2520）一种N，和G（2374）S，作为使用SEQ ID所示的氨基酸序列定义NO ：序列表中的参考序列，在NS3蛋白编码区6，NS5A蛋白编码区，或NS5B蛋白编码区。

公开(公告)号：EP1826269B1

公开(公告)日：2012-04-04

申请号：EP05805278.8

申请日：2005-10-26

申请人： EIKEN KAGAKU KABUSHIKI KAISHA ,  JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

发明人： MINEKAWA, Harumi, NASU KOJO EIKEN KAGAKU K.K. ,  NOTOMI, Tsugunori, NASU KOJO EIKEN KAGAKU K.K. ,  YONEKAWA, Toshihiro, NASU KOJO EIKEN KAGAKU K.K. ,  TOMITA, Norihiro, NASU KOJO EIKEN KAGAKU K.K. ,  KUZUHARA, Yoko, NASU KOJO EIKEN KAGAKU K.K. ,  ODAGIRI, Takato, Murayama, Nat. Inst. Infect. Diseases

IPC分类号： C12Q1/70 ,  C12N15/09 ,  C12Q1/68

CPC分类号： C12Q1/701

摘要： An oligonucleotide primer capable of specifically hybridizing with an arbitrary base sequence designed from the base sequence of hemagglutinin of H5 or H7 avian influenza virus; a method of nucleic acid amplification using the primer; a method of diagnosing any infection with H5 or H7 avian influenza virus through detection of nucleic acid amplification; and a kit for influenza diagnosis.

公开(公告)号：EP1956087A1

公开(公告)日：2008-08-13

申请号：EP06810936.2

申请日：2006-09-29

申请人： JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES ,  Tokyo Metropolitan Organization for Medical Research ,  TORAY INDUSTRIES, INC.

发明人： TANABE, Jun-ichic/oPharm. Res. Lab. ,  SONE, Saburo ,  WAKITA, Takaji, c/o Department of Virology II ,  ISHII, Koji ,  SUZUKI, Ryosuke ,  SUZUKI, Tetsuro ,  MIYAMURA, Tatsuo

IPC分类号： C12N15/09 ,  C12N7/00

CPC分类号： C12N7/00 ,  C12N15/86 ,  C12N2770/24243 ,  C12N2770/24252

摘要： The present invention relates to a method for producing infectious hepatitis C virus (HCV) particles, comprising a step of introducing an expression vector into a cell that allows HCV proliferation, such expression vector comprising: DNA sequences encoding the 5' untranslated region, structural proteins, and, if necessary, non-structural proteins of HCV and DNA sequences encoding non-structural proteins and the 3' untranslated region derived from the HCV JFH1 strain, which are located downstream of a polymerase I promoter; and a DNA fragment containing an RNA polymerase I terminator, which is located further downstream thereof.

摘要翻译： 本发明涉及一种生产感染性丙型肝炎病毒（HCV）颗粒的方法，包括将表达载体导入允许HCV增殖的细胞中的步骤，所述表达载体包含：编码5'非翻译区的DNA序列，结构蛋白 ，如果需要，HCV的非结构蛋白和编码非结构蛋白的DNA序列和源自HCV JFH1株的3'非翻译区位于聚合酶I启动子的下游; 和包含位于其下游的RNA聚合酶I终止子的DNA片段。

公开(公告)号：EP1535627A1

公开(公告)日：2005-06-01

申请号：EP03788098.6

申请日：2003-08-13

申请人： Japan Science and Technology Agency ,  JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

发明人： HONDA, Mitsuo ,  Matsuo, Kazuhiro ,  KANEKIYO, Masaru

IPC分类号： A61K39/04 ,  A61K39/00 ,  C12N15/11 ,  C12N15/31

CPC分类号： C07K14/005 ,  A61K39/04 ,  A61K2039/523 ,  C07K16/1054 ,  C12N15/67 ,  C12N2740/16222

摘要： A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which a third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.

摘要翻译： 用具有编码外源性抗原蛋白质的多核苷酸的表达载体转化的重组BCG疫苗，其中所述多核苷酸是其中每个密码子的第三位置被G或C取代而不改变氨基酸的修饰的BCG疫苗。 该重组BCG疫苗具有优异的抗原蛋白表达率，因此能够以与典型BCG疫苗相同的剂量诱导针对目标传染病，癌症等的足够免疫应答。

公开(公告)号：EP1270016A1

公开(公告)日：2003-01-02

申请号：EP01917712.0

申请日：2001-03-30

申请人： Dnavec Research Inc. ,  JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

发明人： KANO, Munehide ,  MATANO, Tetsuro ,  KATO, Atsushi ,  NAGAI, Yoshiyuki ,  HASEGAWA, Mamoru, c/o DNAVEC Research Inc.

IPC分类号： A61K48/00 ,  A61K39/21 ,  A61K35/76 ,  A61P31/18

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/57 ,  C12N2740/15034 ,  C12N2760/18843 ,  C12N2760/18871 ,  C12N2800/30

摘要： The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency virus. As a result of intranasal inoculation of vaccine, expression of an antigen protein mediated by Sendai virus vector was detected in intranasal mucous membrane and local lymph nodes and antigen-specific cellular immune response was induced at a significant level. No pathological symptom by vaccination was observed. After vaccination, exposure of simian immunodeficiency virus was performed and the effect was examined. As a result, the amount of virus in plasma significantly decreased, compared with that of the control animal. The vaccine of the present invention is promising as an AIDS vaccine.

摘要翻译： 本发明提供含有编码免疫缺陷病毒病毒蛋白质的仙台病毒载体的疫苗。 通过将编码免疫缺陷病毒的病毒蛋白的仙台病毒鼻内施用于猕猴，本发明人成功地有效地诱导针对免疫缺陷病毒的保护性免疫。 鼻内接种疫苗的结果是在鼻内粘膜和局部淋巴结中检测到仙台病毒载体介导的抗原蛋白的表达，并且在相当程度上诱导抗原特异性细胞免疫应答。 没有观察到接种疫苗的病理症状。 接种后，进行猿猴免疫缺陷病毒的暴露，并检查其效果。 结果，与对照动物相比，血浆中的病毒量显着降低。 本发明的疫苗有希望作为艾滋病疫苗。